$AURA News
Last published 1d ago
- 1d agoAURASTIFEL 2026 HEALTHCARE CONFERENCE - AURA BIOSCIENCES INCEarnings Call TranscriptsAll right, thanks everyone for continuing to join us here at Stiefel's 2026 Healthcare Conference. My name is Dara Azar, senior biotech analyst here. It is my pleasure to welcome Natalie Hollis, president and CEO of Aura
- 2d agoAURAAura Biosciences, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 8.01 Item 9.01
- 2d agoAURAAura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswirePhase 3 CoMpass trial on track for topline data in 2H 2027; all participants have completed treatment visits
- 2d agoAURAAura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswirePhase 3 CoMpass trial on track for topline data in 2H 2027; all participants have completed treatment visits Established relationship with industry-leading CDMO providing designated manufacturing capacity for bel-sar
- 1w agoAURAAura Biosciences to Participate in Upcoming Investor ConferenceGlobeNewswireBOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers,
- 1mo agoAURAMorgan Stanley 24th Annual Global Healthcare Conference - AURA BIOSCIENCES INCEarnings Call TranscriptsGood afternoon, everyone. I'm Sean Lyman, Head of US Mid-Cap Biotech Equity Research at Morgan Stanley, and welcome to Morgan Stanley's Global Healthcare Conference. Before we commence, to make you aware of some importan
- 1mo agoAURAMorgan Stanley 24th Annual Global Healthcare Conference - AURA BIOSCIENCES INCEarnings Call TranscriptsGood afternoon, everyone. I'm Sean Lyman, Head of US Mid-Cap Biotech Equity Research at Morgan Stanley, and welcome to Morgan Stanley's Global Healthcare Conference. Before we commence, to make you aware of some importan
- 2mo agoAURAAura Biosciences to Participate in Upcoming Investor ConferenceGlobeNewswireBOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers,
- 2mo agoAURAAura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA) ("Aura" or the "Company"), a clinical-stage biotechnology company developing a potentially transformative first-in-class
- 3mo agoAURAAura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswirePhase 3 CoMpass trial fully enrolled with 108 patients, exceeding enrollment target; on track for topline data in 2H 2027 Strategic operating plan refined to focus on development of bel-sar in ocular oncology Interim
- 4mo agoAURAAura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of DirectorsGlobeNewswireBOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today
- 5mo agoAURAAura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal MelanomaGlobeNewswireEnrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial Topline data from the 15-month primary endpoint expected in the second half of 2027 BOSTON, June 01, 2026 (GLOBE NEWSWIRE) --
- 5mo agoAURATD COWEN 7TH ANNUAL ONCOLOGY INNOVATION SUMMIT: INSIGHTS FOR ASCO & EHA - AURA BIOSCIENCES INCEarnings Call TranscriptsGood afternoon and welcome once again to TD Cowan's 7th Annual Oncology Innovation Summit. I'm Phil Nadeau, one of the biotech analysts here at Cowan. It's my pleasure to do a fireside chat with Aura. We have with us tod
- 5mo agoAURAAura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA) ("Aura" or the "Company"), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ
- 6mo agoAURAAura Biosciences to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced
- 6mo agoAURAAura Biosciences Reports First Quarter 2026 Financial Results and Business HighlightsGlobeNewswirePhase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors Strengthened balance
- 6mo agoAURAAura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireBOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today
- 6mo agoAURAAura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded WarrantsGlobeNewswireBOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today
- 6mo agoAURAAura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireBOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today
- 6mo agoAURAAura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment CompletionGlobeNewswireNatalie Holles, seasoned industry executive with significant rare disease operational and commercialization experience, appointed Chief Executive Officer and President and member of the Board of Directors Acceleration
- 7mo agoAURAAura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsGlobeNewswireAccelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 12-month Stability
- 8mo agoAURAAura Biosciences to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today
- 11mo agoAURAAura Biosciences to Participate in the 8th Annual Evercore Healthcare ConferenceGlobeNewswireBOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function,
- 11mo agoAURAFDMTNBPNovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 ForwardGlobeNewswireCadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract
- 12mo agoAURAAura Biosciences Reports Third Quarter 2025 Financial Results and Business HighlightsGlobeNewswireAura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint Immune Profiling Data Reveal Bel-sar's Potential to Convert ‘Cold'
- 1y agoAURAAura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireBOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function,
- 1y agoAURAAura Biosciences Reports Second Quarter 2025 Financial Results and Business HighlightsGlobeNewswireContinued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC) Strengthened Balance Sheet with $75 Million Equity
- 1y agoAURAAura Biosciences Announces Pricing of Public Offering of Common Stock and WarrantsGlobeNewswireBOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today
- 1y agoAURAAura Biosciences Announces Proposed Public Offering of Common Stock and WarrantsGlobeNewswireBOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today
- 1y agoAURAAura Biosciences Reports First Quarter 2025 Financial Results and Business HighlightsGlobeNewswireFirst Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025 Strengthened Leadership Team with the Appointment of
- 1y agoAURAAura Biosciences to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced
- 1y agoAURAAura Biosciences Announces Appointment of Teresa Bitetti to Board of DirectorsGlobeNewswireBOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today
- 1y agoAURAAura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business HighlightsGlobeNewswirePositive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; Supports Front-Line Treatment Potential Clinical Pipeline Continues to
- 1y agoAURAPositive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology CongressGlobeNewswireClinical Complete Responses Observed with Single Low-Dose of Bel-sar in Patients with Intermediate and High-Risk NMIBC with Robust Cell-Mediated Immunity and Urothelial Field Effect Favorable Safety Profile; Only Grade
- 1y agoAURAAura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology CongressGlobeNewswireAura will Participate in the Research Forum at the 40th Annual European Association of Urology Congress Aura will Host a Virtual Urologic Oncology Investor Event Featuring Key Opinion Leaders at 4:30 pm Eastern Time
- 1y agoAURAAura Biosciences to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today
- 1y agoAURAAura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceGlobeNewswireBOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today
- 1y agoAURAAura Biosciences Reports Third Quarter 2024 Financial Results and Business HighlightsGlobeNewswirePositive Phase 2 End of Study Data with Bel-sar in Early-Stage Choroidal Melanoma; Ongoing Phase 3 CoMpass Trial Recently Received Authorization to Start Enrolling Patients in Europe Multiple Clinical Complete
- 2y agoAURAMultiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 TrialGlobeNewswireClinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors Favorable Safety Profile Observed; Only Grade 1
- 2y agoAURAAura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal MelanomaGlobeNewswireBel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile Aura to Host a Virtual Ocular Oncology Investor Event Featuring Key Opinion Leaders Today at 8:00 am ET
- 2y agoAURAAura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024GlobeNewswireBOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies to treat a range of solid tumors designed to preserve organ
- 2y agoAURAAura Biosciences to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies to treat a range of solid tumors designed to preserve organ
- 2y agoAURAAura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual MeetingGlobeNewswireBOSTON, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies to treat a range of solid tumors designed to preserve organ
- 2y agoAURAAura Biosciences Reports Second Quarter 2024 Financial Results and Business HighlightsGlobeNewswireCompany to Present Early Non-muscle Invasive Bladder Cancer (NMIBC) Data from Ongoing Phase 1 Trial at a Urologic Oncology Investor Event in October 2024 Phase 2 End of Study Data Evaluating Suprachoroidal
- 2y agoAURAAura Biosciences to Participate in the Jefferies Global Healthcare ConferenceGlobeNewswireBOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the
- 2y agoAURAAura Biosciences to Host Virtual KOL Event "Pioneering a New Standard of Care In Ocular Oncology" on May 29, 2024GlobeNewswireBOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the
- 2y agoAURAAura Biosciences Reports First Quarter 2024 Financial Results and Business HighlightsGlobeNewswireContinued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024 Strong Cash Position Expected
- 2y agoAURAAura Biosciences to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the
- 2y agoAURAAura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsBusiness WireEnrolling Patients in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions; Granted SPA Agreement by FDA Data Expected Mid-2024 from Ongoing Phase 1 Trial in Bladder Cancer (Non-Muscle
- 2y agoAURAAura Biosciences to Participate in Upcoming Investor ConferencesBusiness WireAura Biosciences Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los